CJ to introduce FSAD treatment Femprox

Published: 2003-12-08 06:56:00

Updated: 2003-12-08 06:56:00

CJ announced it entered into an exclusive distribution agreement with the U.S.-based NexMed Inc. on November 21 for the introduction of Femprox, which is effective in treating female sexual arousal disorder (FSAD).

Femprox cream incorporates alprostadil (prostaglandin E1) with NexMed's patented NexACT transdermal drug delivery system, incorporating alprostadil (prostaglandin E1) demonstrated...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.